SANIONA AB (PUBL) (F:30S) — Market Cap & Net Worth
Market Cap & Net Worth: SANIONA AB (PUBL) (30S)
SANIONA AB (PUBL) (F:30S) has a market capitalization of $138.54 Million (€118.50 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #18042 globally and #1675 in its home market, demonstrating a -8.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SANIONA AB (PUBL)'s stock price €0.86 by its total outstanding shares 138030134 (138.03 Million). Also see 30S current and non-current assets for a full breakdown of the balance sheet.
SANIONA AB (PUBL) Market Cap History: 2019 to 2026
SANIONA AB (PUBL)'s market capitalization history from 2019 to 2026. Data shows change from $406.66 Million to $138.54 Million (-14.52% CAGR). Also see 30S operating cash flow for how efficiently the company converts equity into cash flow.
SANIONA AB (PUBL) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SANIONA AB (PUBL)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest SANIONA AB (PUBL) stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.71x
SANIONA AB (PUBL)'s market cap is 0.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.09x
SANIONA AB (PUBL)'s market cap is 1.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $148.14 Million | $10.48 Million | -$410.90 Million | 14.14x | N/A |
| 2022 | $40.42 Million | $15.28 Million | -$211.57 Million | 2.65x | N/A |
| 2023 | $53.49 Million | $16.84 Million | -$95.81 Million | 3.18x | N/A |
| 2024 | $112.64 Million | $334.67 Million | $188.71 Million | 0.34x | 0.60x |
| 2025 | $309.51 Million | $434.40 Million | $284.67 Million | 0.71x | 1.09x |
Competitor Companies of 30S by Market Capitalization
Companies near SANIONA AB (PUBL) in the global market cap rankings as of September 20, 2026. Review SANIONA AB (PUBL) tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to SANIONA AB (PUBL) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
SANIONA AB (PUBL) Historical Marketcap From 2019 to 2026
Between 2019 and today, SANIONA AB (PUBL)'s market cap moved from $406.66 Million to $ 138.54 Million, with a yearly change of -14.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €138.54 Million | -55.24% |
| 2025 | €309.51 Million | +174.79% |
| 2024 | €112.64 Million | +110.56% |
| 2023 | €53.49 Million | +32.34% |
| 2022 | €40.42 Million | -72.71% |
| 2021 | €148.14 Million | -54.78% |
| 2020 | €327.58 Million | -19.44% |
| 2019 | €406.66 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of SANIONA AB (PUBL) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $138.54 Million USD |
| MoneyControl | $138.54 Million USD |
| MarketWatch | $138.54 Million USD |
| marketcap.company | $138.54 Million USD |
| Reuters | $138.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SANIONA AB (PUBL)
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more